Top

News & Events

Client News

Client News

Dimerix to Present Analysis of DMX-200 Phase 2a Clinical Trial in Chronic Kidney Disease at the American Society of Nephrology (ASN) Annual Kidney Week 2017

Dimerix Limited (ASX: DXB), is pleased to announce that a detailed analysis of the data from the DMX-200 Phase 2a clinical trial in Chronic Kidney Disease will be announced to the ASX coincident with its feature as a poster presentation at the American Society of Nephrology (ASN) Kidney Week 2017, to be held in New Orleans, Louisiana from October 31 to November 5, 2017.

Read more »

Clinigen Receives EC Approval for Updates to Cardioxane Product Information

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, announces that its Commercial Medicines operation received a European Commission (EC) approval to update the current product information for Cardioxane.

Read more »

Biopharma Stages a Strong Recovery Over the First Half Even as M&A deals Disappoint, While Unprecedented Amounts of Money Flow in Medtech but Not Towards Smaller Innovators

LONDON, BOSTON, SAN FRANCISCO, TOKYO - Today EP Vantage, the independent news and analysis arm of Evaluate Ltd, releases its 2017  half-year reports on pharma & biotech and medtech sector performance.  Report authors Elizabeth Cairns and Jon Gardner provide their expert viewpoints, powered by Evaluate data and consensus forecasts.

Read more »

Japanese Pharmaceutical Market Set to Grow 3.3% (CAGR) Between 2017 and 2022, Significantly Lower than the Worldwide Outlook (6.5% CAGR)

LONDON, BOSTON, SAN FRANCISCO, TOKYO — According to life science commercial intelligence firm, Evaluate, the enforcement of a much more stringent pricing revision policy in Japan, both for new products as well as off-patent brands, is behind the decline of the products currently on the market which are forecast to drop about 2% annually in sales through 2022.

Read more »

Recce Confirms Delivery by Intravenous Drip for its RECCE® 327 Antibiotic, with FDA IND Submission on Track

Sydney, Australia - Recce Limited (ASX: RCE), a pre-clinical stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, today confirmed it remains on track to submit its Investigative New Drug Application (IND) to the US Food and Drug Administration (FDA) for its lead compound RECCE® 327, following additional positive pre-clinical study data on mode of administration, drug clearance, dosing and efficacy.

Read more »

BioScience Managers Appoints Elizabeth Klein as Investment Consultant in the UK to Support BioScience Managers’ and Downing’s Life Sciences Investments

London, UK and Melbourne, Australia Leading healthcare investment specialist BioScience Managers Limited (BioScience Managers) announces today that it has appointed Elizabeth Klein as an Investment Consultant, to facilitate BioScience Managers’ UK investment deal flow, in particular to support its collaboration entered into in December 2016 with London-based investment firm Downing LLP. Her primary focus will be on sourcing and reviewing investment opportunities for BioScience Managers’ and the Downing FOUR Healthcare Share Class Venture Capital Trust (VCT) plc (Downing FOUR Healthcare).

Read more »

e-Therapeutics Announces Outcome of Strategic Review and Future Plans

Oxford, UK, e-Therapeutics plc (AIM: ETX):  Upon the completion of Ray Barlow’s first three months as CEO of e-Therapeutics, the Company outlines below the conclusion of the strategic review for its investors and other stakeholders.

Read more »

Epi Analyzer: Blockbusters Out, Highly Targeted Therapies In

LONDON, BOSTON, SAN FRANCISCO, TOKYO — Today life science commercial intelligence leader, Evaluate, released case studies highlighting the value of granular patient segmentation and epidemiological data to support commercial valuations, whitespace identification and product differentiation ultimately leading to enhanced portfolio decision-making. Therapy areas covered include: CAR-T, MPS-III and Age-related Macular Degeneration.

Read more »

Recce achieves milestone with volume production of antibiotic compounds to support clinical trials

SYDNEY, Australia: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, today announced its new automated manufacturing facility in Sydney is now producing at name-plate standard its antibiotic compounds at volumes in preparation for human clinical trials.

Read more »

Clinigen and Sarepta Therapeutics launch a Managed Access Program to treat patients with Duchenne Muscular Dystrophy amenable to exon 51 skipping

Clinigen Group plc’s (AIM: CLIN, 'Clinigen') Idis Managed Access division and Sarepta Therapeutics Inc. (NASDAQ: SRPT) have initiated a Managed Access Program (MAP) for eteplirsen in certain geographies to treat Duchenne Muscular Dystrophy (DMD) patients amenable to exon 51 skipping. This MAP (also known as an early / expanded access, or named patient program) provides a mechanism through which physicians can legally and ethically prescribe eteplirsen to patients who meet pre-specified medical criteria and where funding can be secured.

Read more »

Abzena and Telix sign licence agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies

Cambridge, UK and Melbourne, Australia – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licence agreement with Telix Pharmaceuticals Limited (‘Telix’), a biopharmaceutical company specializing in the development and commercialisation of radiopharmaceuticals for diagnostic (imaging) and therapeutic use (the “Agreement”).

Read more »

Clinigen Group plc: Year end trading update 2017

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides a trading update for the 12 months ended 30 June 2017.

Read more »

Rapid, Near-patient Genomic Tests for Infectious Disease set to Revolutionize Antibiotic Prescribing and Patient Care

London, UK and Carlsbad, CA, USA – DNA Electronics (‘DNAe’), the inventor of semiconductor DNA sequencing technology and developer of a new, revolutionary sample-to-result diagnostic platform to rapidly determine the causative agent of infectious diseases, provided an update on its LiDia™ test for serious bloodstream infections (BSI), a condition which can lead to the potentially life-threatening complication of sepsis if not diagnosed and treated quickly. The test is on track for commercial launch in 2018.

Read more »

Dimerix Reports Positive Results from Phase 2a Trial of DMX-200 in Chronic Kidney Disease

MELBOURNE, Australia: Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company today announced positive safety and efficacy data (primary endpoint met) following its now completed 27 patient Phase 2a Proof of Concept, Dose Escalation Study in Chronic Kidney Disease (CKD) for lead program, DMX-200. Dimerix will now progress with the design for the planned Phase 2b DMX-200 study.

Read more »

Health for Life Capital™ Participates in Financing of Two Connected Health companies: Machtfit in Germany and Push Doctor in the UK

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation, today announces that it has participated in two financing rounds in Machtfit and Push Doctor, both companies specialising in connected health, reflecting the growth potential in this innovative area. The investments were made from Seventure’s Health for Life Capital™ investment vehicle.

Read more »

Agendia’s MammaPrint® Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the American Society of Clinical Oncology (ASCO®) has today published revised early-stage breast cancer guidelines in the Journal of Clinical Oncology, titled The Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early Stage Invasive Breast Cancer: American Society of Clinical Oncology Practice Guideline.

Read more »

Abzena and OBI Pharma sign ThioBridge™ licence agreement

Cambridge, UK, Taipei, Taiwan – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licensing agreement and a master services and clinical supply agreement with OBI Pharma, a Taiwanese biopharmaceutical company (‘OBI’, TPEx: 4174).

Read more »

Clinigen and Cumberland Pharmaceuticals obtain FDA approval for Totect® in the U.S.

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the ‘Group’), the global pharmaceutical and services company and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX, ‘Cumberland’), a U.S. specialty pharmaceutical company, today announce they have obtained FDA approval for Totect® (dexrazoxane hydrochloride) in the U.S.

Read more »

Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome

Stevenage, UK – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted AUT00206 an Orphan Drug Designation for the treatment of Fragile X Syndrome, the most common known cause of inherited learning disabilities.

Read more »

Agendia’s MammaPrint® recommended by the 2017 St. Gallen International Breast Cancer Guidelines in significant update

IRVINE, CA and AMSTERDAM - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the 15th St. Gallen International Breast Cancer Guidelines recently published in Annals of Oncology have recommended the MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test for the third time to help guide treatment decision-making for patients with early-stage breast cancer.

Read more »

Health for Life Capital™ Participates in $13.2m Financing of Japanese Microbiome Leader Anaeropharma Science

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces that it has participated in a $13.1m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventure’s Health for Life Capital™ investment vehicle.

Read more »

MammaPrint® Late Recurrence (20yr) Low Risk result identifies breast cancer patients with 97% survival at 20-years with limited endocrine therapy treatment

IRVINE, Calif. & AMSTERDAM - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics announces new data published today in JAMA Oncology.1 Following the retrospective analysis and 20-year follow-up data from the prospective, randomized Stockholm Tamoxifen Trial, a Late Recurrence (20yr) Low Risk result (referred to as the ‘indolent’ threshold in the study) of the MammaPrint® Test has demonstrated the ability to identify a sub-group of patients with exceedingly low metastatic risk 20 years after diagnosis. These patients, of which a majority only received two years of hormonal therapy, had an observed 20-year breast cancer specific survival of 97%.

Read more »

Health for Life Capital™ Further Expands Israeli Portfolio with Investment in Microbiome App Developer

Paris, France - Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces that it has invested in Israel-based personalized nutrition microbiome app company DayTwo through its Health for Life Capital™ investment vehicle, as part of a $12m series A fundraising.

Read more »

Mission Therapeutics Appoints Scientific Advisory Board

Cambridge, UK – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat serious diseases including mitochondrial diseases, neurodegeneration, inflammation and cancer, today announced the formation of its inaugural Scientific Advisory Board (SAB).
 

Read more »

BioGeneration Ventures Fund III Secures EUR 66m, exceeding EUR 50m target

Naarden, The Netherlands – BioGeneration Ventures (BGV), the early stage life sciences venture capital firm with funds focussed on European biotechnology companies, announces today an investment by the European Investment Fund (EIF) and other new investors in BGV III, taking the total capital commitments to EUR 66m, out of a maximum EUR 75m. The Fund is supported by the “InnovFin – EU Finance for Innovators” initiative under Horizon 2020 and the European Fund for Strategic Investments.

Read more »